How to maximize the efficacy of taxanes in breast cancer

Cancer Treatment Reviews

Volumn 31, Issue SUPPL. 4, 2005, Pages

  Tubiana Hulin, M ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Anthracycline taxane; Combination therapy; Docetaxel capecitabine; Efficacy; Paclitaxel gemcitabine; Taxane; Taxane platin; Trastuzumab taxane

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; PREDNISONE; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; METASTASIS; NEUTROPENIA; SEPSIS; TREATMENT PLANNING;

EID: 28944444651     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(05)80002-7     Document Type: Article

References (22)

1. Rahman ZU Frye DK Smith TL et al. Results and long-term follow up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. A reference Cancer 85 1 1999 104-111
2. Fossati R Confalonieri C Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomised trials involving 31,510 women J Clin Oncol 16 1998 3439-3460
3. Ghersi D Wilcken N Simes J Donoghue E Taxane containing regimens for metastatic breast cancer (Cochrane Review). The Cochrane Library, Issue 2. 2005 2005 John Wiley and Sons Ltd Chichester UK
4. Gralow J Optimising the treatment of metastatic breast cancer Breast Cancer Res Treat 89 Suppl 1 2005 S9-S15
5. Jones S Erban J Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J Clin Oncol 23 24 2005 5542-5551
6. Bontembal M Braun JJ Creemers GJ et al. Phase III study comparing AT to FAC as first-line chemotherapyin patients with metastatic breast cancer EJC Supplements 2003 S201
7. Luck HJ Thomssen C Untch M et al. multicentric phase III study in firstline treatment of advanced metastatic breast cancer Epirubicin/ paclitaxel vs Epirubicin/cyclophosphamide 2000 ASCO Abstract 88
8. Biganzoli L Cufer T Bruning P Coleman R Duchateau L Calvert AH Gamucci T Twelves C Fargeot P Epelbaum R Lohrisch C Piccart MJ Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial J Clin Oncol 20 14 2002 3114-3121
9. Sledge GW Neuberg D Bernardo P Ingle JN Martino S Rowinsky EK Wood WC Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193) J Clin Oncol 21 4 2003 588-592
10. Nabholtz JM Falkson G Campos D et al. Docetaxel and doxorubicin (AT) compared to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial J Clin Oncol 21 2003 968-975
11. Spielmann M Tubiana-Hulin M Namer M Mansouri H Bougnoux P Tubiana-Mathieu N Lotz V Eymard JC Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: A randomised phase II trial Br J Cancer 86 5 2002 692-697
12. Bonneterre J Dieras V Tubiana-Hulin M et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer Br J Cancer 91 2004 1466-1471
13. Reyes S et al. ECCO 2003 (Abstract 447).
14. Perez EA Carboplatin in combination therapy for metastatic breast cancer Oncologist 9 5 2004 518-527
15. Fountzilas G Kalofonos HP Dafni U et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group Ann Oncol 15 10 2004 1517-1526
16. O'Shaughnessy J Miles D Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results J Clin Oncol 20 12 2002 2812-2823
17. Albain KS Nag S Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 14S 2004 510 (July 15 Suppl)
18. Colomer R What is the best schedule for administration of gemcitabine-taxane? Cancer Treatment Rev 31 Suppl 4 2005 23-28
19. Baselga J Tabernero JM Weekly docetaxel in breast cancer. Applying clinical data to patient therapy Oncologist 6 Suppl. 3 2001 26-29
20. Burstein HJ Manola J Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 18 6 2000 1212-1219
21. Salmon DJ Leyland-Jones B Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 2001 783-792
22. Marty M Cognetti F Maraninchi D et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: Results of a randomized phase II trial by the M77001 study group J Clin Oncol 2005